Cited 0 times in
Staged diabetes management according to individual patient insulin resistance and beta-cell function ameliorates glycaemic control in type 2 diabetes mellitus.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, SH | - |
dc.contributor.author | Hur, KY | - |
dc.contributor.author | Kim, DJ | - |
dc.contributor.author | Ahn, CW | - |
dc.contributor.author | Kang, ES | - |
dc.contributor.author | Cha, BS | - |
dc.contributor.author | Lim, SK | - |
dc.contributor.author | Huh, KB | - |
dc.contributor.author | Lee, HC | - |
dc.date.accessioned | 2010-12-22T06:51:30Z | - |
dc.date.available | 2010-12-22T06:51:30Z | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 0300-0664 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/757 | - |
dc.description.abstract | OBJECTIVE: The current consensus algorithm for management of type 2 diabetes is based on the fasting glucose concentration and glycated haemoglobin A(1c) (HbA(1c)) level. We applied a new therapeutic strategy by assessing insulin secretion and insulin resistance, in addition to glucose concentrations in individual patients.
DESIGN AND PATIENTS: We enrolled 193 patients with type 2 diabetes. The patients were assigned to one of six groups according to insulin secretion measured by the serum fasting C-peptide concentration and insulin resistance measured by an insulin tolerance test (ITT). The two groups were treated differently: 108 patients were treated using a new staged diabetes management (SDM) strategy and 85 patients continued with conventional therapy. MEASUREMENTS: We compared metabolic variables in the two groups at baseline and 12 months after enrollment. RESULTS: In patients treated with the SDM strategy, fasting glucose concentration decreased from 9.8 +/- 2.1 to 8.2 +/- 1.7 mmol/l (P < 0.001). Postprandial 2-h glucose concentration decreased from 14.19 +/- 3.34 to 12.27 +/- 3.24 mmol/l (P < 0.001). HbA(1c) level decreased from 8.37 +/- 1.42% to 7.72 +/- 1.39% (P < 0.001). About 43% of the new SDM group achieved an HbA(1c) of < 7.0% compared with 25% of patients in the conventional treatment group. CONCLUSIONS: The new SDM strategy, based on individual data on insulin resistance and insulin secretion, may provide valuable clinical benefits in non-obese Korean patients with type 2 diabetes. | - |
dc.language.iso | en | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Algorithms | - |
dc.subject.MESH | Blood Glucose | - |
dc.subject.MESH | Body Weights and Measures | - |
dc.subject.MESH | Clinical Protocols | - |
dc.subject.MESH | Diabetes Mellitus, Type 2 | - |
dc.subject.MESH | Fasting | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hemoglobin A, Glycosylated | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Individuality | - |
dc.subject.MESH | Insulin Resistance | - |
dc.subject.MESH | Insulin-Secreting Cells | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.title | Staged diabetes management according to individual patient insulin resistance and beta-cell function ameliorates glycaemic control in type 2 diabetes mellitus. | - |
dc.type | Article | - |
dc.identifier.pmid | 18248646 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0300-0664&date=2008&volume=69&issue=4&spage=549 | - |
dc.contributor.affiliatedAuthor | 김, 대중 | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1111/j.1365-2265.2008.03199.x | - |
dc.citation.title | Clinical endocrinology | - |
dc.citation.volume | 69 | - |
dc.citation.number | 4 | - |
dc.citation.date | 2008 | - |
dc.citation.startPage | 549 | - |
dc.citation.endPage | 555 | - |
dc.identifier.bibliographicCitation | Clinical endocrinology, 69(4). : 549-555, 2008 | - |
dc.identifier.eissn | 1365-2265 | - |
dc.relation.journalid | J003000664 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.